GLP-1 & compounded medication availability in Mississippi (2026)
Mississippi is the plainest demonstration of what this page family exists to do. Nine of the ten rows below say No, and every one of those Nos traces to a document you can read: the state’s diet-medication rule, a 2024 board order on compounded GLP-1s, and a 2026 statement signed by three Mississippi boards at once. We would rather publish this page than pretend the map has no edges. One line does ship here today, and the rest of this page explains, with citations, why the others do not.
The Mississippi matrix: one Yes, nine Nos
| Product line | Available in Mississippi? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | No | N/A | Not offered routinely here. The regulator section carries the state’s 2024 order and what little of it remains open. |
| GLP-1/GIP (compounded tirzepatide) | No | N/A | Same basis as the semaglutide row; the same cited order covers both drug classes. |
| NAD+ | Yes | 8–10 business days | The one line that ships: NAD+ is neither a peptide under the 2026 joint statement nor a weight-loss medication under the diet-medication rule. |
| Sermorelin | No | N/A | Paused for Mississippi pending review of whether the 2026 joint statement reaches it. Lifting this is a compliance decision, not a copy edit. |
| Glutathione | No | N/A | A formulary gap in every state, not a Mississippi finding. |
| BPC-157 | No | N/A | We carry it elsewhere; we do not ship it here. The signed tri-board statement is cited below. |
| TB-500 | No | N/A | Same answer, same signed statement, cited in the peptide section. |
| KPV | No | N/A | Outside our formulary everywhere, and covered by Mississippi’s statement besides. |
| Epitalon | No | N/A | Carried in other states as an injectable; a No for Mississippi per the cited statement. |
| MOTS-c | No | N/A | A No here for the same cited reason, even though its federal record differs from its siblings’. |
This is the most No-heavy page OrderlyMeds publishes, and it stays up on purpose: if we will not show you Mississippi as it is, you have no reason to trust our Texas page either. Facts reviewed November 16, 2026.
Why no research peptide ships to Mississippi
Everywhere else in this page family, OrderlyMeds carries BPC-157, TB-500, Epitalon and MOTS-c as compounded injectables and declines only KPV. Mississippi is the exception: all five rows are No at once, because of one signed document, quoted and linked here, not paraphrased from a blog.
On August 19, 2026, the Mississippi Board of Nursing, the Mississippi Board of Pharmacy, and the Mississippi State Board of Medical Licensure jointly stated that “under no circumstances is it permissible for a healthcare provider to compound, administer, or dispense a non-FDA approved or research-grade peptide to a patient,” a prohibition that expressly includes advising, recommending, supplying, prescribing, and administering — and that patient consent forms describing a product as research-grade do not mitigate or eliminate the provider’s professional or legal liability. Source: Joint statement of the three Mississippi boards, signed August 19, 2026 (PDF).
Each line’s own federal record still appears below, unchanged, because it is true no matter which state page you are reading, and because the statement above is a Mississippi position layered on top of that record, not a replacement for it.
BPC-157 and Mississippi
Not shipped to Mississippi addresses. The tri-board statement cited above is the reason. Its federal record, which applies everywhere:
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 and Mississippi
A No for Mississippi under the same signed statement. The federal facts attached to this line:
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV and Mississippi
Doubly unavailable: KPV sits outside the OrderlyMeds formulary in every state, and Mississippi’s statement covers it independently.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon and Mississippi
Carried as an injectable in other states; not dispensed into Mississippi, per the statement cited at the top of this section. Its record:
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c and Mississippi
Also a No here. Its federal history genuinely differs from the four lines above, set out below, but the Mississippi answer does not change with it.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Mississippi’s medical and pharmacy regulators actually say
Mississippi’s position was not announced in a press release. It accumulated, document by document, between 2023 and 2026. Here is the stack, oldest rule first, each piece linked to the state’s own text.
Mississippi State Board of Medical Licensure rules provide that off-label use of any medication lacking FDA approval for the treatment of weight loss is prohibited when administered solely for weight loss, with waivers available only by board action for good cause (30 Miss. Admin. Code Part 2640, Rule 1.5(F)). Source: MSBML Administrative Code (current edition, Rule 1.5).
By order of July 17, 2024 — explained in supplemental guidance of August 6, 2024 — the board granted a limited exemption from Rule 1.5(F) for compounded GLP-1 and GIP drug classes in exactly two situations: a patient-specific clinical need not met by a commercially available product, or the medication’s presence on FDA’s drug-shortage list; the prescriber must also confirm the supplying pharmacy’s active-ingredient verification testing and certificate of analysis, and prescribing outside the exemption violates board regulations. Source: MSBML Supplemental Guidance and Board Order (PDF).
FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025 — which closed the Mississippi exemption’s shortage prong for both drug classes, leaving only the documented patient-specific clinical-need pathway. Source: FDA statement on GLP-1 supply and compounding policies.
The Mississippi Board of Pharmacy has separately notified compounding licensees that salt-form semaglutide compounding does not meet FDA requirements and may result in enforcement action by FDA and/or the board. Source: Mississippi Board of Pharmacy compounding notice (PDF).
Any pharmacy outside Mississippi that ships, mails, or delivers prescription drugs into the state must hold a nonresident pharmacy permit from the Board of Pharmacy, with a pharmacist-in-charge holding a Mississippi pharmacist license (Miss. Code Ann. §73-21-106). Source: Miss. Code Ann. §73-21-106 (PDF).
Mississippi’s telemedicine rules themselves are not the obstacle: a valid physician-patient relationship may be established with an exam that is not in person if the technology provides the physician the same information as a face-to-face exam — while treatment based on a simple questionnaire without an appropriate exam violates board policy (30 Miss. Admin. Code Part 2635, Rules 5.4–5.5). Source: MSBML Administrative Code (Part 2635, Chapter 5).
Our reading of that stack, stated plainly: the routine telehealth weight-loss offering OrderlyMeds runs in most states is not what Mississippi’s documents contemplate, and the one remaining GLP-1 pathway is individual enough that we will not advertise it as availability. So the rows above say No. If the board’s position moves, or our compliance review concludes the documented clinical-need pathway supports a real offering, the feed behind this page changes and the page follows, in whichever direction the facts point.
Mississippi availability FAQs
Is compounded semaglutide available in Mississippi?
No, not as a routine offering. Mississippi’s medical-licensure rules reach prescribing for weight loss directly, and the board’s 2024 order leaves only a narrow, individually documented pathway. Rather than stretch that pathway, we show the row as a No until our compliance review says otherwise. The cited documents are in the regulator section.
Can I get BPC-157, TB-500, Epitalon or MOTS-c shipped to Mississippi?
No. In August 2026 Mississippi’s medical, nursing, and pharmacy boards issued a joint statement against providers supplying non-FDA-approved research-grade peptides to patients, with no exemption pathway. Those four rows are No for Mississippi, with the signed statement cited on this page.
Does anything on this page ship to Mississippi?
Yes. NAD+, which is neither a peptide covered by the 2026 joint statement nor a weight-loss medication under the board’s diet-medication rule. It ships to Mississippi addresses in 8–10 business days.
Is telehealth itself the problem in Mississippi?
No. Mississippi’s telemedicine rules accept an exam that is not in person when the technology gives the provider the same information as a face-to-face visit, though a questionnaire alone is never enough. What limits this page is the state’s position on the medications, not on telehealth.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
